Published in final edited form as:

Bioorg Med Chem Lett. 2009 December 15; 19(24): 6872–6876. doi:10.1016/j.bmcl.2009.10.085.

Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-ones: toward selective Abl inhibitors

Christophe Antczak^{1,*}, Darren R. Veach¹, Christina N. Ramirez¹, Maria A. Minchenko¹, David Shum¹, Paul A. Calder¹, Mark G. Frattini², Bayard Clarkson¹, and Hakim Djaballah¹

¹Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA

²Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA

Abstract

We report the design, synthesis and structure-activity relationship (SAR) of a series of novel pyrido[2,3-*d*]pyrimidin-7-one compounds as potent Abl kinase inhibitors. We evaluate their specificity profile against a panel of human recombinant kinases, as well as their biological profile toward a panel of well characterized cancer cell lines. Our study reveals that substitutions in the -3 and -4 positions of the phenylamino moiety lead to improved potency and improved selectivity both in target-based and cell based assays. Altogether, our results provide an insight into the SAR of pyrido[2,3-*d*]pyrimidin-7-ones for the development of drug candidates with improved potency and selectivity for the targeted treatment of CML.

Keywords

Pyridopyrimidines; CML; Abl kinase; inhibitor

Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy that accounts for up to 20% of adult leukemias. The pathological hallmark of CML is the Philadelphia chromosome present in >90% of patients. The Philadelphia chromosome results from a translocation between chromosomes 9 and 22, leading to the juxtaposition of the Abelson tyrosine kinase (Abl) and breakpoint cluster (Bcr) genes. The resulting Bcr-Abl fusion gene encodes for the constitutively active Bcr-Abl tyrosine kinase, responsible for growth factor-independent cell growth and resistance to apoptosis. Both lead to the uncontrolled proliferation of myeloid cells. Imatinib mesylate (GleevecTM, Figure 1) is a 2-phenylaminopyrimidine Bcr-Abl inhibitor approved by the FDA for the treatment of CML and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Although an initial response is achieved with Imatinib in patients, resistance may develop in advanced phases of CML because of the appearance of mutations in Bcr-Abl, leading to patient relapse. Therefore, novel agents able to overcome resistance to Imatinib such as the Bcr-Abl inhibitor Dasatinib¹ (Figure 1) are needed for the effective treatment of CML.

Pyrido[2,3-*d*]pyrimidines were originally characterized as inhibitors of the fibroblast growth factor receptor (FGFR), epidermal growth factor receptor (EGFR), platelet-derived growth

Corresponding author: Christophe Antczak, PhD, High Throughput Screening Core Facility, MSKCC; 415 E 68th Street, ZRC-1919; New York, NY 10021; antczakc@mskcc.org, tel.:(646) 888-2203, fax:(646) 888-3166.

factor (PDGFR), and Src protein tyrosine kinases^{2–4}. Members of this chemical class have been shown to be potent inhibitors of the Abl and Bcr-Abl tyrosine kinases and to induce apoptosis of the CML cell line K562^{5–7}. Importantly, derivatives of pyrido[2,3-*d*]pyrimidines such as the pyrido[2,3-*d*]pyrimidin-7-one [PD166326] **1** (Figure 1) are active both in Imatinib-sensitive and in resistant cancer cell lines expressing mutant Bcr-Abl^{8, 9}, and PD166326 has demonstrated marked antileukemic activity in vivo¹⁰. Pyrido[2,3-*d*]pyrimidin-7-ones therefore constitute an attractive class of drug candidates for the treatment of sensitive and refractory CML. While pyrido[2,3-*d*]pyrimidine-based tyrosine kinase inhibitors have been described as pan-kinase inhibitors, to our knowledge SAR studies aimed at characterizing and improving the selectivity of PD166326 analogs toward Abl has not been reported. In an attempt to fill this gap, we embarked in the design of novel pyrido[2,3-*d*]pyrimidin-7-one derivatives. The co-crystal structure of **1** with Abl kinase reveals a feature that we decided to exploit in the design of a focused library of pyrido[2,3-*d*]pyrimidin-7-ones: a solvent accessible opening in the back end of the ATP-binding site may tolerate additional functional groups (Figure 2A). The C-2 phenylamino moiety protrudes from the binding pocket and is solvent-exposed (Figure 2B). Molecular modeling and docking studies show that the 3- or 4- position on this arene (Figure 2B) can be functionalized with a variety of groups that may improve solubility and kinase selectivity without decreasing Abl binding affinity. For this reason, we decided to explore the structure-activity relationship of 2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-one derivatives substituted at positions 3- and 4- of the arene as an avenue in the search of more selective Abl inhibitors (Figure 1). For this goal, we generated 19 new compounds by coupling a variety of aniline derivatives with 6-(2,6-dichlorophenyl)-2-methanesulfonyl-8-methyl-8*H*-pyrido[2,3-*d*]pyrimidin-7-one. Compounds **1–19** were synthesized using methods previously described^{2, 11}.

Table 1 summarizes the potency of R¹ derivatives with substituents in the 3- position of the phenylamino moiety toward Abl. As expected, we found using a coupled assay previously described¹² that the IC₅₀ of the reference compound PD166326 **1** toward Abl was in the same range as previously reported (2.8 vs. 8 nM)⁹. Interestingly, polar substituents increased the potency of R¹ derivatives (**5**>**2**>**4**), compared to **1**, while substituting the hydroxyl moiety of **1** with a methyl group induced a 10-fold loss in activity toward Abl. Of note, we have identified two analogs with a slightly improved potency compared to the reference compound PD166326: the amino- (**5**) and hydroxyl- (**2**) substituted R¹ derivatives. Table 2 summarizes the potency toward Abl of R² derivatives with substituents in the 4- position of the phenylamino moiety. Similarly to R¹ derivatives, we observe a higher potency for those derivatives substituted with polar groups (**8**>**13**=**17**>**7**>**12**) compared to hydrophobic substituents (**9**>**10**>**11**). For example, a 10-fold difference in potency is observed between the R² derivative **13** substituted with an amino group compared to the fluoro derivative **10**. In addition, for the R² amino derivatives, a loss of potency is observed when the amino group in this position is capped with hydrophobic moieties such as acetate (**14**), chloroacetamide (**15**), or *N*-*tert*-butoxycarbonylaminopropanamide (**18**). In contrast, when this amino group is substituted with a polar moiety such as a propanediol (**17**), no loss of potency is observed. As a confirmation of our observations, we observe a good correlation (R²=0.7) between the potency of our derivatives toward Abl and their ClogP (Figure 3); potency decreases as hydrophobicity increases, and the most potent compound we have identified (**8**) is also the most hydrophilic (Figure 3). Altogether, our results strongly suggest that polar substituents in positions 3- and 4- of the phenylamino moiety improve the potency of 2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-one derivatives. Furthermore, we conclude that position 4- tolerates bulky groups, since analog **8** substituted with a glycoside in this position is the most potent derivative that we have identified; analog **8**, with an IC₅₀ of 1.4 nM toward Abl, has a 2-fold increased potency compared to the reference compound

PD166326. Our observations therefore validate our hypothesis that positions -3 and -4 of the aminophenyl moiety tolerate additional functional groups; polar substituents in these positions actually improve the potency of 2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-one derivatives.

While the activity of PD166326 (**1**) toward Abl and Src is well documented, we sought to assess a broad specificity profile for this compound, as well as for the new analogs we have synthesized. For this purpose, we constituted a panel of six human recombinant kinases: five tyrosine kinases (Abl, PDGFR, VEGFR, Src and C-kit) and one serine/threonine kinase (p38- α). As expected, **1** was potent toward PDGFR and Src tyrosine kinases, with an IC₅₀ of 45 and 43 nM for these kinases respectively (Table 3). Importantly, we found that the reference compound **1** inhibits p38- α and VEGFR quite potently in addition to Abl (IC₅₀=140 nM and 281 nM respectively), while it is significantly less potent toward C-Kit, with an IC₅₀ of 636 nM. To our knowledge, this observation constitutes the first report of the inhibitory activity of PD166326 toward the serine/threonine p38- α kinase, while inhibition of p38- α kinase by other pyrido[2,3-*d*]pyrimidine compounds has been previously described¹³. This result underlines the importance of our study, as a better understanding of the SAR of pyridopyrimidinones is necessary to design more selective derivatives. As predicted, all members of our focused library potently inhibit Abl, with their IC₅₀ ranging from 1.4 to 30 nM. However, their compared selectivity toward Abl, PDGFR and p38- α varied, and they were generally less potent toward VEGFR and C-Kit (Table 3). The selectivity of our analogs toward Abl compared to p38- α ranged from 2 to 72-fold. Interestingly, we identified a clear trend among the new compounds we have synthesized: the selectivity of R² derivatives for Abl compared to p38- α was 2 to 25-fold, while it ranged from 34 to 72 fold for R¹ derivatives. This important observation strongly suggests that substitutions in the 3- position of the phenylamino moiety increase the selectivity of pyrimidopyrimidinone derivatives for Abl compared to p38- α . We found that analog **2** had a similar potency toward Abl compared to the reference compound PD166326 **1**, but was roughly 2-fold more selective for Abl vs. PDGFR and VEGFR, and had no activity toward C-Kit. Analog **2** is the most selective derivative we have identified, with a selectivity ratio for Abl vs. other kinases ranging from 17 to greater than 385 fold (Table 3); this result constitutes a significant improvement compared to the selectivity profile of the reference compound **1**. We conclude that the important SAR we have defined should allow the design of pyrimidopyrimidinone derivatives with greatly enhanced selectivity for the Abl kinase.

To test the biological relevance of our findings we performed the cytotoxicity profiling of our pyridopyrimidine derivatives against a panel of seven well characterized cancer cell lines, using an assay we had previously reported¹⁴. As expected, the 19 derivatives of our focused library are extremely potent toward the CML cell lines K562, MEG-01, KU812 and Kasumi-4, which are Philadelphia chromosome positive (Table 4); most derivatives have an IC₅₀ lower than 10 nM toward these cell lines. We also found that all compounds were potent toward ALL-3 cells, derived from a patient with acute lymphoblastic leukemia treated at MSKCC and characterized as Philadelphia chromosome positive. Interestingly, while ALL-3 cells were refractory to Imatinib (IC₅₀ = 333 nM, Figure 4), we found that the reference compound PD166326 **1** was potent toward these cells (IC₅₀ = 7.7 nM, Figure 4), as well as Dasatinib (IC₅₀ = 0.4 nM, Figure 4). This result was expected since ALL-3 cells express Bcr-Abl, and confirms the previous observation that pyrimidopyrimidine derivatives are active in Imatinib-resistant cell lines^{8,9}. Importantly, most compounds in our library had potent cytotoxic activity toward ALL-3 cells – including analog **2** with the improved kinase selectivity profile (IC₅₀ = 37 nM, Figure 4) – highlighting the great potential of the class of 2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-ones as drug candidates for patients refractory to Imatinib. When we assessed the cytotoxicity of our novel derivatives toward the human acute T-cell leukemia cell line Jurkat and the human Mantle cell lymphoma NCEB-1 cell

line – both Philadelphia chromosome negative – as a control, we found as expected that none of the compounds we tested had potent cytotoxic activity toward these cells. This result indicates that our new derivatives are selective toward Philadelphia chromosome positive cells, emphasizing their potential for the targeted therapy of CML patients.

In summary, our study proved successful, in that we have identified more potent and more selective analogs of PD166326 among our focused library of 19 novel pyrido[2,3-*d*]pyrimidin-7-one derivatives. In addition, we have defined clear trends in the SAR for this class of compounds that should lead to the discovery of novel drug candidates with improved potency and selectivity profile for the targeted therapy of CML.

Acknowledgments

The authors wish to thank the members of the High Throughput Screening Core Facility for their help during the course of this study. The HTS Core Facility is partially supported by Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research, the Experimental Therapeutics Center of MSKCC, the William Randolph Hearst Fund in Experimental Therapeutics, the Lilian S Wells Foundation and by an NIH/NCI Cancer Center Support Grant 5 P30 CA008748-44. D.V. and B.C. gratefully acknowledge the MeadWestvaco Corporation for financial support.

References

1. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. *N Engl J Med*. 2006; 354:2531–2541. [PubMed: 16775234]
2. Boschelli DH, Wu Z, Klutchko SR, Showalter HD, Hamby JM, Lu GH, Major TC, Dahring TK, Batley B, Panek RL, Keiser J, Hartl BG, Kraker AJ, Klohs WD, Roberts BJ, Patmore S, Elliott WL, Steinkampf R, Bradford LA, Hallak H, Doherty AM. *J Med Chem*. 1998; 41:4365–4377. [PubMed: 9784112]
3. Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, Panek RL, Major TC, Olsewski B, Ryan MJ, Dahring T, Lu GH, Keiser J, Amar A, Shen C, Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty AM. *J Med Chem*. 1997; 40:2296–2303. [PubMed: 9240345]
4. Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW. *Biochem Pharmacol*. 2000; 60:885–898. [PubMed: 10974196]
5. Dorsey JF, Jove R, Kraker AJ, Wu J. *Cancer Res*. 2000; 60:3127–3131. [PubMed: 10866298]
6. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. *Oncogene*. 2002; 21:8804–8816. [PubMed: 12483533]
7. Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B. *Cancer Res*. 2002; 62:4244–4255. [PubMed: 12154026]
8. von Bubnoff N, Veach DR, Miller WT, Li W, Sanger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. *Cancer Res*. 2003; 63:6395–6404. [PubMed: 14559829]
9. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. *Clin Cancer Res*. 2003; 9:1267–1273. [PubMed: 12684394]
10. Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr. *Blood*. 2005; 105:3995–4003. [PubMed: 15657179]
11. Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM. *J Med Chem*. 1998; 41:3276–3292. [PubMed: 9703473]
12. Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, Larson SM. *Nucl Med Biol*. 2005; 32:313–321. [PubMed: 15878500]

13. Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Gerlach M, Missio A, Cotten M, Muller S, Daub H. Mol Cell Proteomics. 2004; 3:1181–1193. [PubMed: 15475568]
14. Shum D, Radu C, Kim E, Cajuste M, Shao Y, Seshan VE, Djaballah H. J Enzyme Inhib Med Chem. 2008; 23:931–945. [PubMed: 18608772]

Figure 1. Structure of PD166326 (1) and general structure of the 19 derivatives of our 2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-one focused library.

Figure 2.
X-ray structure rendering of PD166326 (**1**) co-crystallized with Abl kinase. **A:** Overall view.
B: View centered on PD166326. The red and blue arrow indicate the 3- and 4-positions on the C-2 phenylamino moiety respectively.

Figure 3.

Influence of the hydrophobicity of 2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-one compounds on their potency toward Abl. Highlighted compounds: **1** (PD166326), Abl IC₅₀ = 2.8 ± 0.6 nM, CLogP = 4.1; **2**, Abl IC₅₀ = 2.6 ± 0.4 nM, CLogP = 4.5; **3**, Abl IC₅₀ = 22 ± 10 nM, CLog P = 6.2; **8**, Abl IC₅₀ = 1.4 ± 0.1 nM, CLog P = 3.0.

Figure 4.

Dose response of selected compounds in the Alamar Blue assay toward ALL-3 cells.

Dasatinib, IC₅₀ = 0.4 nM; PD166326 (**1**), IC₅₀ = 7.7 nM; **17**, IC₅₀ = 15 nM; **2**, IC₅₀ = 35 nM; **5** IC₅₀ = 135 nM; Imatinib, IC₅₀ = 333 nM.

Table 1

2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-ones: variation of 3-phenyl substituents.

Compound	R ¹	Abl IC ₅₀ (nM)	cLogP
2		2.6 ± 0.4	4.5
1		2.8 ± 0.6	4.1
3		22 ± 10	6.2
4		4.9 ± 1.2	3.3
5		2.5 ± 0.4	3.9

Compound	R ¹	Abl IC ₅₀ (nM)	cLogP
6		5.0 ± 0.6	4.1

Table 2

2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-ones: variation of 4-phenyl substituents.

Compound	R ²	Abl IC ₅₀ (nM)	cLogP
7		5.3 ± 0.6	4.5
8		1.4 ± 0.1	3.0
9		13 ± 3.2	6.3
10		21 ± 14	5.3
11		30 ± 20	5.6
12		8.2 ± 1.0	4.3

Compound	R ²	Abl IC ₅₀ (nM)	cLogP
2.3 ± 0.5	3.9
	4.8 ± 0.6	4.1
	7.6 ± 1.9	4.8
	4.7 ± 0.9	3.6
	2.3 ± 0.5	3.6

Compound	R ²	Abl IC ₅₀ (nM)	cLogP
18		12 ± 7	5.4
19		3.6 ± 0.1	4.4

Table 3Summary of the kinase specificity profile of 2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-ones.

Compound	Abl IC ₅₀ (nM)	p38- α IC ₅₀ (nM)	PDGFR IC ₅₀ (nM)	Src IC ₅₀ (nM)	VEGFR IC ₅₀ (nM)	C-Kit IC ₅₀ (nM)
10	21	50 (2)	47 (2)	921 (44)	N.E.	290 (14)
19	3.6	10 (3)	14 (4)	35 (10)	44 (12)	235 (65)
16	4.7	34 (7)	26 (6)	18 (4)	104 (22)	239 (51)
8	1.4	15 (11)	15 (11)	30 (21)	69 (49)	250 (179)
12	8.2	110 (13)	83 (10)	9.2 (1)	245 (30)	N.E.
17	2.3	32 (14)	42 (18)	38 (17)	158 (69)	421 (183)
R ² derivatives	11	30	488 (16)	492 (16)	546 (18)	N.E.
	9	13	224 (17)	341 (26)	296 (23)	766 (59)
	15	7.6	135 (18)	433 (57)	292 (38)	N.E.
	7	5.3	105 (20)	223 (42)	455 (86)	N.E.
	13	2.3	51 (22)	36 (16)	51 (22)	491 (213)
R ¹ derivatives	14	4.8	108 (23)	43 (9)	159 (33)	N.E.
	18	12	299 (25)	213 (18)	415 (35)	N.E.
	3	22	752 (34)	234 (11)	354 (16)	N.E.
	1	2.8	140 (50)	43 (15)	281 (100)	636 (227)
	6	5	251 (50)	150 (30)	59 (12)	N.E.
	5	2.5	133 (53)	38 (15)	47 (19)	N.E.
	4	4.9	330 (67)	66 (13)	297 (61)	N.E.
	2	2.6	187 (72)	43 (17)	552 (212)	N.E.

N.E.: no effect; IC₅₀ > 1,000 nM; (x): selectivity ratio for Abl.

Table 4

Summary of the cell based antitumor activity of 2-(phenylamino)pyrido[2,3-*d*]pyrimidin-7-ones.

Compound	Ph+ CML					Ph+ ALL	Ph-leuk.	Ph-lymp.
	Abl IC ₅₀ (nM)	K562 IC ₅₀ (nM)	MEG-01 IC ₅₀ (nM)	KU812 IC ₅₀ (nM)	Kasumi-4 IC ₅₀ (nM)			
8	1.4	<10	<10	<10	<10	55	N.E.	N.E.
13	2.3	<10	<10	<10	<10	165	6,500	N.E.
17	2.3	25	<10	<10	<10	15	N.E.	N.E.
5	2.5	<10	<10	<10	<10	135	N.E.	N.E.
2	2.6	<10	<10	<10	<10	35	5,000	N.E.
1	2.8	<10	<10	<10	<10	<10	2,100	N.E.
19	3.6	<10	<10	<10	<10	<10	900	N.E.
16	4.7	350	<10	<10	<10	165	3,600	N.E.
14	4.8	<10	<10	<10	<10	35	N.E.	N.E.
4	4.9	<10	<10	<10	<10	<10	4,200	N.E.
6	5	<10	<10	<10	<10	35	4,600	N.E.
7	5.3	<10	<10	<10	<10	55	1,500	5,300
15	7.6	<10	<10	<10	<10	45	660	N.E.
12	8.2	<10	<10	<10	<10	200	3,700	N.E.
18	12	90	<10	<10	<10	2,800	N.E.	N.E.
9	13	<10	<10	<10	<10	545	1,300	N.E.
10	21	<10	<10	<10	<10	170	3,700	N.E.
3	22	60	25	<10	<10	650	N.E.	N.E.
11	30	55	35	<10	<10	790	N.E.	N.E.

CML: chronic myelogenous leukemia, ALL: acute lymphoblastic leukemia, leuk.: leukemia, lymph.: lymphoma.